Blackmores

Blackmores, an Australian pharmaceutical preparation manufacturer, reported total carbon emissions of approximately 2.2 million kg CO2e for the year 2023. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. For 2023, Scope 1 emissions were approximately 350,000 kg CO2e, including mobile combustion and fugitive emissions. Scope 2 emissions, primarily from purchased electricity, amounted to approximately 900,000 kg CO2e. Scope 3 emissions were reported at approximately 550,000 kg CO2e, with significant contributions from business travel and waste generated in operations.

In 2022, Blackmores' total emissions were approximately 1.66 million kg CO2e, comprising approximately 300,000 kg CO2e for Scope 1 and 855,000 kg CO2e for Scope 2. Scope 3 emissions for that year totalled approximately 500,000 kg CO2e.

The company's emissions data is cascaded from Blackmores Limited, with SBTi, RE100, and RTZ targets inherited from Kirin Holdings Company, Limited at cascade level 2. While specific reduction targets for Blackmores are not detailed, the company's sustainability reporting indicates a focus on emissions management. Previous years' data shows varying total emissions, with approximately 13.5 million kg CO2e reported for 2021 and 2020, primarily attributed to Scope 2 emissions at the time. In 2019, total emissions were approximately 8.34 million kg CO2e, with Scope 2 emissions at around 4.86 million kg CO2e. In 2018, total emissions were approximately 8.33 million kg CO2e, comprising Scope 1, Scope 2, and Scope 3. Blackmores is committed to reducing its environmental impact, as evidenced by its participation in initiatives cascaded from its parent company.